Open access
Comparative Efficacy and Safety of Bruton Tyrosine Kinase and Spleen Tyrosine Kinase Inhibitors in Immune Thrombocytopenia: A Network Meta‐Analysis of Clinical Trials
Ayah Abulehia
R. B. Alshareef
Shorouq Khateeb
Usra I. Ghanem
Amir Abadi
Nora Zatar
Peter R. Bael
Raghad Sweity
H. Ghanem
H. Ayesh
Medicine
Abstract
Targeted kinase inhibitors have shown statistically and clinically significant improvements in platelet response among patients with primary ITP, supporting their utility as effective targeted therapeutic strategies. We evaluated the efficacy and safety of Bruton tyrosine kinase (BTK) and spleen tyrosine kinase (SYK) inhibitors in primary immune thrombocytopenia (ITP) using network meta‐analysis.